Cross-Sector entity
earnings is the sole category represented across all 1 tracked stories. Takeda is most often covered alongside Protagonist Therapeutics, which appears in 1 of these 1 story. Takeda appears in 1 tracked Cross-Sector story from March 17, 2026. The tracked stories average 2 original sources each.
1 verified story tracked
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Takeda is most often covered alongside Protagonist Therapeutics, which appears in 1 of these 1 story. Takeda appears in 1 tracked Cross-Sector story from March 17, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Takeda. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings Release
Official financial results and conference calls scheduled for both companies.
Pre-Earnings Market Activity
Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
Takeda Deal Restructuring
Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
